{"medgen_id":"C1843355","name":"Neonatal ichthyosis-sclerosing cholangitis syndrome","attribute_content":[],"alternate_names":["Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis","Ichthyosis-sclerosing cholangitis syndrome"],"keywords":[],"gard_id":"10583","id":"1776","type":"Disease","symbol":"ILVASC","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011874\"}","{\"db\":\"OMIM\",\"id\":\"607626\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"59303\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ichthyosis%2C+leukocyte+vacuoles%2C+alopecia%2C+and+sclerosing+cholangitis/3739\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10583\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011874\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607626\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[]}
{"medgen_id":"C1843116","name":"Congenital bile acid synthesis defect 1","attribute_content":[],"alternate_names":["3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY","3-alpha beta-hydroxy-delta-5-c27-steroid oxidoreductase, deficiency of"],"keywords":[],"gard_id":"9813","id":"595","type":"Disease","symbol":"CBAS1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011906\"}","{\"db\":\"OMIM\",\"id\":\"607765\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79301\"}","{\"db\":\"OMIM\",\"id\":\"607765\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9813\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011906\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607765\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[]}
{"medgen_id":"C1853297","name":"Maturity-onset diabetes of the young type 8","attribute_content":[],"alternate_names":["Diabetes and pancreatic exocrine dysfunction","Diabetes mellitus MODY type 8","Diabetes-pancreatic exocrine dysfunction syndrome"],"keywords":[],"gard_id":"10662","id":"2870","type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012348\"}","{\"db\":\"OMIM\",\"id\":\"609812\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"552\"}","{\"db\":\"OMIM\",\"id\":\"609812\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DPED\"}","{\"db\":\"OMIM\",\"id\":\"609812\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MODY8\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10662\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012348\",\"ref_field\":\"name\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24624459\",\"@Source\":\"PubMed\"},{\"$\":\"NBK190101\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":["DPED","MODY8"]}
{"medgen_id":"C0342701","name":"Transcolabamin II deficiency","attribute_content":[],"alternate_names":["TC II DEFICIENCY","TCN2 DEFICIENCY","Transcobalamin II deficiency"],"keywords":[],"gard_id":"12338","id":"4288","type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010149\"}","{\"db\":\"OMIM\",\"id\":\"275350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"859\"}","{\"db\":\"OMIM\",\"id\":\"275350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TC II DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"275350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TCN2 DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Transcobalamin+II+deficiency/9416\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Transcobalamin II deficiency\"}","{\"db\":\"SNOMED CT\",\"id\":\"237934001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Transcobalamin II deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12338\",\"ref_field\":\"gard_id\"}"],"alternate_symbols":[]}
{"medgen_id":"C5231483","name":"NEUROMUSCULAR OCULOAUDITORY SYNDROME","attribute_content":[],"alternate_names":[],"keywords":[],"id":"43258","type":"Disease","symbol":"NMOAS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032890\"}","{\"db\":\"OMIM\",\"id\":\"618733\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"603405.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603405.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603405.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603405.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618733\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618733\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[]}
{"medgen_id":"C0018784","name":"Sensorineural hearing loss","attribute_content":[],"alternate_names":["Sensorineural deafness","Sensorineural hearing impairment","sensorineural hearing loss disorder"],"keywords":[],"id":"6180","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000374\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000407\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001753\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001916\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008538\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008553\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008565\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008576\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008611\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008613\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008614\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020678\"}","{\"db\":\"MeSH\",\"id\":\"D006319\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000407\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sensorineural deafness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000407\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sensorineural hearing impairment\"}","{\"db\":\"ClinGen Hearing Loss Variant Curation Expert Panel\",\"id\":\"ad55f8aa-c75a-44f6-9a6e-2344d0525a05\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"sensorineural hearing loss disorder\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sensorineural+hearing+loss/6504\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000407\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"60700002\",\"ref_field\":\"name\"}"],"alternate_symbols":[]}
{"medgen_id":"C0027708","name":"Nephroblastoma","attribute_content":[],"alternate_names":["Wilm's tumor","Wilms' tumor"],"keywords":[],"id":"32458","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000115\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002667\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0019004\"}","{\"db\":\"MeSH\",\"id\":\"D009396\"}","{\"db\":\"OMIM\",\"id\":\"PS194070\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"654\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002667\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Wilm's tumor\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002667\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25081006\",\"ref_field\":\"name\"}"],"alternate_symbols":[]}
{"medgen_id":"C3808046","name":"Breathing dysregulation","attribute_content":[],"alternate_names":["Abnormal breathing","Difficult to breathe"],"keywords":[],"id":"25341","type":"Finding","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005957\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormal breathing\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Difficult to breathe\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005957\",\"ref_field\":\"name\"}"],"alternate_symbols":[]}
{"medgen_id":"CN280969","name":"PSEUDO-TORCH SYNDROME 3","attribute_content":[],"alternate_names":[],"keywords":[],"id":"52512","type":"Disease","symbol":"PTORCH3","xrefs":["{\"db\":\"OMIM\",\"id\":\"618886\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"600556.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600556.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618886\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618886\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[]}
{"medgen_id":"C0279702","name":"Clear cell carcinoma of kidney","attribute_content":[],"alternate_names":["Clear cell RCC","Clear cell renal cell carcinoma","Clear-cell metastatic renal cell carcinoma (subtype)","Cystic-multilocular variant","Hypernephroma","Renal cell carcinoma, clear cell, somatic"],"keywords":[],"id":"18267","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006770\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006770\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Clear cell renal cell carcinoma\"}","{\"db\":\"SNOMED CT\",\"id\":\"188251003\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypernephroma\"}","{\"db\":\"SNOMED CT\",\"id\":\"254915003\",\"ref_field\":\"name\"}"],"alternate_symbols":[]}
{"medgen_id":"C1833021","public_definition":"WFS1 Wolfram syndrome spectrum disorder (WFS1-WSSD) is a progressive neurodegenerative disorder characterized by onset of diabetes mellitus (DM) and optic atrophy (OA) before age 16 years, and typically associated with other endocrine abnormalities, sensorineural hearing loss, and progressive neurologic abnormalities (cerebellar ataxia, peripheral neuropathy, dementia, psychiatric illness, and urinary tract atony). Although DM is mostly insulin-dependent, overall the course is milder (with lower prevalence of microvascular disease) than that seen in isolated DM. OA typically results in significantly reduced visual acuity in the first decade. Sensorineural hearing impairment ranges from congenital deafness to milder, sometimes progressive, hearing impairment.","name":"Autosomal dominant nonsyndromic deafness 6","attribute_content":[],"alternate_names":["DEAFNESS, AUTOSOMAL DOMINANT 14","DEAFNESS, AUTOSOMAL DOMINANT 38","DEAFNESS, AUTOSOMAL DOMINANT 6","WFS1-Related Disorders"],"keywords":[],"id":"4904","type":"Disease","symbol":"DFNA6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010963\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90635\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 14\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 38\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"OMIM\",\"id\":\"606201.0023\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL DOMINANT 6\"}","{\"db\":\"Genetic Alliance\",\"id\":\"WFS1-Related+Disorders/9476\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WFS1-Related Disorders\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DFNA14\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DFNA38\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010963\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK4144\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600965\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301750\",\"@Source\":\"PubMed\"},{\"$\":\"NBK4144\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":["DFNA14","DFNA38"]}
{"medgen_id":"C3888099","public_definition":"Bestrophinopathies, the spectrum of ophthalmic disorders caused by pathogenic variants in BEST1, are typically characterized by retinal degeneration. The four recognized phenotypes are the three autosomal dominant disorders: Best vitelliform macular dystrophy (BVMD), BEST1 adult-onset vitelliform macular dystrophy (AVMD), and autosomal dominant vitreoretinochoroidopathy (ADVIRC); and autosomal recessive bestrophinopathy (ARB). Onset is usually in the first decade (except AVMD in which onset is age 30 to 50 years). Slow visual deterioration is the usual course. Choroidal neovascularization can occur in rare cases. ADVIRC is also associated with panophthalmic involvement including nanophthalmos, microcornea, hyperopia, and narrow anterior chamber angle with angle closure glaucoma.","name":"Vitreoretinochoroidopathy","attribute_content":[],"alternate_names":["Autosomal dominant Vitreoretinochoroidopathy","VITREORETINOCHOROIDOPATHY WITH MICROCORNEA, GLAUCOMA, AND CATARACT","VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT, WITH NANOPHTHALMOS","VRCP autosomal dominant","Vitreoretinochoroidopathy dominant"],"keywords":[],"gard_id":"5507","id":"6115","type":"Disease","symbol":"VRCP","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008662\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"263347\"}","{\"db\":\"Orphanet\",\"id\":\"3086\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VITREORETINOCHOROIDOPATHY WITH MICROCORNEA, GLAUCOMA, AND CATARACT\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT, WITH NANOPHTHALMOS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Vitreoretinochoroidopathy+dominant/7409\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Vitreoretinochoroidopathy dominant\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADVIRC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5507\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneTests\",\"id\":\"319390\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1167\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301346\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1167\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22234150\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["ADVIRC"]}
{"medgen_id":"C2745945","public_definition":"Bestrophinopathies, the spectrum of ophthalmic disorders caused by pathogenic variants in BEST1, are typically characterized by retinal degeneration. The four recognized phenotypes are the three autosomal dominant disorders: Best vitelliform macular dystrophy (BVMD), BEST1 adult-onset vitelliform macular dystrophy (AVMD), and autosomal dominant vitreoretinochoroidopathy (ADVIRC); and autosomal recessive bestrophinopathy (ARB). Onset is usually in the first decade (except AVMD in which onset is age 30 to 50 years). Slow visual deterioration is the usual course. Choroidal neovascularization can occur in rare cases. ADVIRC is also associated with panophthalmic involvement including nanophthalmos, microcornea, hyperopia, and narrow anterior chamber angle with angle closure glaucoma.","name":"Vitelliform macular dystrophy type 2","attribute_content":[],"alternate_names":["Best disease","Best macular dystrophy","Best vitelliform macular dystrophy, multifocal","Macular degeneration, polymorphic vitelline","VITELLIFORM MACULAR DYSTROPHY, EARLY-ONSET","VITELLIFORM MACULAR DYSTROPHY, JUVENILE-ONSET","Vitelliform dystrophy"],"keywords":[],"id":"2720","type":"Disease","symbol":"VMD2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007931\"}","{\"db\":\"OMIM\",\"id\":\"153700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1243\"}","{\"db\":\"OMIM\",\"id\":\"153700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VITELLIFORM MACULAR DYSTROPHY, EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"153700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VITELLIFORM MACULAR DYSTROPHY, JUVENILE-ONSET\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Vitelliform+dystrophy/9457\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Vitelliform dystrophy\"}","{\"db\":\"SNOMED CT\",\"id\":\"90036004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Vitelliform dystrophy\"}","{\"db\":\"OMIM\",\"id\":\"153700\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BMD\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1167\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"153700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301346\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1167\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22234150\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["BMD","VMD"]}
{"medgen_id":"C3888198","public_definition":"Bestrophinopathies, the spectrum of ophthalmic disorders caused by pathogenic variants in BEST1, are typically characterized by retinal degeneration. The four recognized phenotypes are the three autosomal dominant disorders: Best vitelliform macular dystrophy (BVMD), BEST1 adult-onset vitelliform macular dystrophy (AVMD), and autosomal dominant vitreoretinochoroidopathy (ADVIRC); and autosomal recessive bestrophinopathy (ARB). Onset is usually in the first decade (except AVMD in which onset is age 30 to 50 years). Slow visual deterioration is the usual course. Choroidal neovascularization can occur in rare cases. ADVIRC is also associated with panophthalmic involvement including nanophthalmos, microcornea, hyperopia, and narrow anterior chamber angle with angle closure glaucoma.","name":"Bestrophinopathy, autosomal recessive","attribute_content":[],"alternate_names":[],"keywords":[],"id":"491","type":"Disease","symbol":"ARB","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012733\"}","{\"db\":\"OMIM\",\"id\":\"611809\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139455\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bestrophinopathy%2C+autosomal+recessive/7813\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1167\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611809\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301346\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1167\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22234150\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[]}
{"medgen_id":"C5231390","public_definition":"Sitosterolemia is characterized by: Hypercholesterolemia (especially in children) which (1) shows an unexpected significant lowering of plasma cholesterol level in response to low-fat diet modification or to bile acid sequestrant therapy; or (2) does not respond to statin therapy; Tendon xanthomas or tuberous (i.e., planar) xanthomas that can occur in childhood and in unusual locations (heels, knees, elbows, and buttocks); Premature atherosclerosis, which can lead to angina, aortic valve involvement, myocardial infarction, and sudden death; Hemolytic anemia, abnormally shaped erythrocytes (stomatocytes), and large platelets (macrothrombocytopenia). On occasion, the abnormal hematologic findings may be the initial presentation or the only clinical feature of this disorder. Arthritis, arthralgias, and splenomegaly may sometimes be seen and one study has concluded that \"idiopathic\" liver disease could be undiagnosed sitosterolemia. The clinical spectrum of sitosterolemia is probably not fully appreciated due to underdiagnosis and the fact that the phenotype in infants is likely to be highly dependent on diet.","name":"Sitosterolemia 1","attribute_content":[],"alternate_names":[],"keywords":[],"id":"43302","type":"Disease","symbol":"STSL1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020747\"}","{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK131810\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23556150\",\"@Source\":\"PubMed\"},{\"$\":\"NBK131810\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[]}
{"medgen_id":"C0342907","public_definition":"Sitosterolemia is characterized by: Hypercholesterolemia (especially in children) which (1) shows an unexpected significant lowering of plasma cholesterol level in response to low-fat diet modification or to bile acid sequestrant therapy; or (2) does not respond to statin therapy; Tendon xanthomas or tuberous (i.e., planar) xanthomas that can occur in childhood and in unusual locations (heels, knees, elbows, and buttocks); Premature atherosclerosis, which can lead to angina, aortic valve involvement, myocardial infarction, and sudden death; Hemolytic anemia, abnormally shaped erythrocytes (stomatocytes), and large platelets (macrothrombocytopenia). On occasion, the abnormal hematologic findings may be the initial presentation or the only clinical feature of this disorder. Arthritis, arthralgias, and splenomegaly may sometimes be seen and one study has concluded that \"idiopathic\" liver disease could be undiagnosed sitosterolemia. The clinical spectrum of sitosterolemia is probably not fully appreciated due to underdiagnosis and the fact that the phenotype in infants is likely to be highly dependent on diet.","name":"Sitosterolemia","attribute_content":[],"alternate_names":["Phytosterolemia","Plant sterol storage disease","Retention of dietary cholesterol and abnormal retention of non-cholesterol sterols in the body"],"keywords":[],"gard_id":"7653","id":"3731","type":"Disease","symbol":"STSL","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008863\"}","{\"db\":\"OMIM\",\"id\":\"PS210250\",\"type\":\"Phenotypic series\"}","{\"db\":\"OMIM\",\"id\":\"PS215250\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"2882\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7653\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneTests\",\"id\":\"3093\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sitosterolemia/6620\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS210250\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"238104009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK131810\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23556150\",\"@Source\":\"PubMed\"},{\"$\":\"NBK131810\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[]}
{"medgen_id":"C0011860","public_definition":"Type 2 diabetes is a disorder characterized by abnormally high blood sugar levels. In this form of diabetes, the body stops using and making insulin properly. Insulin is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source. When blood sugar levels are high (such as after a meal), the pancreas releases insulin to move the excess glucose into cells, which reduces the amount of glucose in the blood.Most people who develop type 2 diabetes first have insulin resistance, a condition in which the body's cells use insulin less efficiently than normal. As insulin resistance develops, more and more insulin is needed to keep blood sugar levels in the normal range. To keep up with the increasing need, insulin-producing cells in the pancreas (called beta cells) make larger amounts of insulin. Over time, the beta cells become less able to respond to blood sugar changes, leading to an insulin shortage that prevents the body from reducing blood sugar levels effectively. Most people have some insulin resistance as they age, but inadequate exercise and excessive weight gain make it worse, greatly increasing the likelihood of developing type 2 diabetes.Type 2 diabetes can occur at any age, but it most commonly begins in middle age or later. Signs and symptoms develop slowly over years. They include frequent urination (polyuria), excessive thirst (polydipsia), fatigue, blurred vision, tingling or loss of feeling in the hands and feet (diabetic neuropathy), sores that do not heal well, and weight loss. If blood sugar levels are not controlled through medication or diet, type 2 diabetes can cause long-lasting (chronic) health problems including heart disease and stroke; nerve damage; and damage to the kidneys, eyes, and other parts of the body.","name":"Diabetes mellitus type 2","attribute_content":[],"alternate_names":["DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST","DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO","Diabetes mellitus Type II","NIDDM diabetes mellitus","Non-insulin dependent diabetes","Noninsulin-dependent diabetes","Noninsulin-dependent diabetes mellitus","Type 2 diabetes","Type II diabetes"],"keywords":[],"id":"4949","type":"Disease","symbol":"NIDDM","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005965\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100652\",\"type\":\"secondary\"}","{\"db\":\"MeSH\",\"id\":\"D003924\"}","{\"db\":\"OMIM\",\"id\":\"125853\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"125853\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST\"}","{\"db\":\"OMIM\",\"id\":\"611145.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST\"}","{\"db\":\"OMIM\",\"id\":\"611145.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST\"}","{\"db\":\"OMIM\",\"id\":\"142410.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"600733.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"600733.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"600733.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"600733.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"600733.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"600733.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Diabetes mellitus Type II\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NIDDM diabetes mellitus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Non-insulin dependent diabetes\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Noninsulin-dependent diabetes\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Noninsulin-dependent diabetes mellitus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type 2 diabetes\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type II diabetes\"}","{\"db\":\"OMIM\",\"id\":\"125853\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"T2D\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Diabetes+mellitus+type+2/8215\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"44054006\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"type-2-diabetes\",\"ref_field\":\"public_definition\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005978\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"125853\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"PLoS Currents, 2011\",\"@Type\":\"general\",\"URL\":{\"$\":\"http://knol.google.com/k/raluca-mihaescu/genetic-risk-profiling-for-prediction/20113liwenx5c/9?collectionId=28qm4w0q65e4w.50#\"}},{\"@Abbrev\":\"EGAPP, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23492873\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ES, 2012\",\"@Type\":\"practice guideline\",\"ID\":[{\"$\":\"22962670\",\"@Source\":\"PubMed\"},{\"$\":\"3431581\",\"@Source\":\"pmc\"}]}]}","alternate_symbols":["T2D"]}
{"medgen_id":"C2608083","public_definition":"ATP8B1 deficiency encompasses a phenotypic spectrum ranging from severe to intermediate to mild, based on an individual's clinical findings and laboratory test results, including liver biopsy. Severe ATP8B1 deficiency is characterized by onset of symptoms of cholestasis (pruritus and attacks of jaundice) within the first few months of life. Secondary manifestations such as coagulopathy (due to vitamin K deficiency), malabsorption, and poor weight gain may present earlier than age three months. Without surgical intervention, cirrhosis and evolution to end-stage hepatic failure and death usually ensue before the third decade. Mild ATP8B1 deficiency is characterized by intermittent episodes of cholestasis manifest as severe pruritus and jaundice; chronic liver damage does not typically develop. In contrast to patients in whom bouts of cholestasis are induced only by particular triggers known to increase risk of cholestasis (drug exposure, shifts in hormonal milieu [including those resulting from ingestion of contraceptive drugs or from pregnancy], coexistent malignancy), some or all bouts of cholestasis in individuals with mild ATP8B1 deficiency have different or unknown triggers.","name":"Benign recurrent intrahepatic cholestasis type 2","attribute_content":[],"alternate_names":["Recurrent familial intrahepatic cholestasis 2"],"keywords":[],"id":"794","type":"Disease","symbol":"BRIC2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011559\"}","{\"db\":\"OMIM\",\"id\":\"605479\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"65682\"}","{\"db\":\"Orphanet\",\"id\":\"99961\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011559\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1297\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605479\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301474\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1297\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[]}
{"medgen_id":"C1856127","public_definition":"Congenital bile acid synthesis defect type 2 is a disorder characterized by cholestasis, a condition that impairs the production and release of a digestive fluid called bile from liver cells. Bile is used during digestion to absorb fats and fat-soluble vitamins, such as vitamins A, D, E, and K. People with congenital bile acid synthesis defect type 2 cannot produce (synthesize) bile acids, which are a component of bile that stimulate bile flow and help it absorb fats and fat-soluble vitamins. As a result, an abnormal form of bile is produced.The signs and symptoms of congenital bile acid synthesis defect type 2 often develop in infancy. Affected infants usually have a failure to gain weight and grow at the expected rate (failure to thrive) and yellowing of the skin and eyes (jaundice) due to impaired bile flow and a buildup of partially formed bile. Excess fat in the feces (steatorrhea) is another feature of congenital bile acid synthesis defect type 2. As the condition progresses, affected individuals can develop liver abnormalities including inflammation or chronic liver disease (cirrhosis). Some individuals with congenital bile acid synthesis defect type 2 cannot absorb certain fat-soluble vitamins, which can result in softening and weakening of the bones (rickets) or problems with blood clotting that lead to prolonged bleeding.If left untreated, congenital bile acid synthesis defect type 2 typically leads to cirrhosis and death in childhood.","name":"Congenital bile acid synthesis defect 2","attribute_content":[],"alternate_names":["Cholestasis with delta(4)-3-oxosteroid 5-beta-reductase deficiency"],"keywords":[],"gard_id":"10045","id":"596","type":"Disease","symbol":"CBAS2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009339\"}","{\"db\":\"OMIM\",\"id\":\"235555\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79303\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10045\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009339\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"congenital-bile-acid-synthesis-defect-type-2\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"235555\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[]}
{"medgen_id":"C0268237","disease_mechanism_id":"273","name":"Mitochondrial complex IV deficiency","attribute_content":[],"alternate_names":["COX deficiency","Complex 4 mitochondrial respiratory chain deficiency","Complex IV deficiency","Cytochrome-c oxidase deficiency","Deficiency of mitochondrial respiratory chain complex4","Hepatic failure, early-onset, and neurologic disorder due to cytochrome C oxidase deficiency"],"keywords":[],"gard_id":"48","id":"5548","type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009068\"}","{\"db\":\"OMIM\",\"id\":\"220110\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254905\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mitochondrial+complex+IV+deficiency/4826\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cytochrome-c oxidase deficiency\"}","{\"db\":\"SNOMED CT\",\"id\":\"67434000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cytochrome-c oxidase deficiency\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506509\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520058\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521398\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530224\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"48\",\"ref_field\":\"gard_id\"}"],"disease_mechanism":"loss of function","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"26425749\",\"@Source\":\"PubMed\"},{\"$\":\"NBK320989\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[]}
{"medgen_id":"C1833104","public_definition":"Permanent neonatal diabetes mellitus (PNDM) is characterized by the onset of hyperglycemia within the first six months of life (mean age: 7 weeks; range: birth to 26 weeks). The diabetes mellitus is associated with partial or complete insulin deficiency. Clinical manifestations at the time of diagnosis include intrauterine growth retardation, hyperglycemia, glycosuria, osmotic polyuria, severe dehydration, and failure to thrive. Therapy with insulin corrects the hyperglycemia and results in dramatic catch-up growth. The course of PNDM varies by genotype.","disease_mechanism_id":"274","name":"Permanent neonatal diabetes mellitus","attribute_content":[],"alternate_names":["DIABETES MELLITUS, PERMANENT NEONATAL 1","Permanent diabetes mellitus of infancy"],"keywords":[],"gard_id":"10457","id":"1095","type":"Disease","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011643\"}","{\"db\":\"OMIM\",\"id\":\"606176\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99885\"}","{\"db\":\"OMIM\",\"id\":\"138079.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, PERMANENT NEONATAL 1\"}","{\"db\":\"OMIM\",\"id\":\"138079.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, PERMANENT NEONATAL 1\"}","{\"db\":\"OMIM\",\"id\":\"606176\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIABETES MELLITUS, PERMANENT NEONATAL 1\"}","{\"db\":\"OMIM\",\"id\":\"606176\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PDMI\"}","{\"db\":\"OMIM\",\"id\":\"606176\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PNDM1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000284792\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500516\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500517\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506518\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506519\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506524\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508859\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514676\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514677\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514687\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514688\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514689\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552543\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552544\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552549\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556824\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556831\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556834\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557910\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10457\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Permanent+neonatal+diabetes+mellitus/5681\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011643\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1447\",\"ref_field\":\"public_definition\"}"],"disease_mechanism":"gain of function","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301620\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1447\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["PDMI","PNDM1"]}
